A questionnaire to assess neurological impairment in multiple sclerosis

Multiple Sclerosis

Volumn 4, Issue 5, 1998, Pages 444-451

  Goodin, Douglas S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clinical trials; Multiple sclerosis; Neurological impairment disability; Questionnaire; Survey

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MALE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PHYSICIAN; QUESTIONNAIRE; SCORING SYSTEM; SELF REPORT;

EID: 0031792215     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/135245898678919474     Document Type: Article

References (36)

1. Kassirer JP. (1995) Managed care and the morality of the market place. N Engl J Med 333: 50-52.
2. Drake DF. (1997) Managed care: a product of market dynamics. J Am Med Assoc 277: 560-563.
3. King RB, Moore B. (1996) Managed care: past, present, and future. Arch Neurol 53: 851-855.
4. Larson E. (1996) The soul of an HMO. Time Magazine, January 22, pp 44-52.
5. Heimoff S. (1996) The rhetoric of prevention. California Medicine. November, pp 23-28.
6. Rosenthal E. (1997) Older doctors and doctors see jobs at stake. New York Times, January 26, p 1.
7. Anderson DW et al. (1992) Revised estimate of the prevalence of multiple sclerosis in the United States. Ann Neurol 31: 333-336.
8. Groves RM. (1989) Survey errors and survey costs. John Wiley and Sons: New York.
9. Solari A et al. (1993) Accuracy of self-assessment of the minimal record of disability in patients with multiple sclerosis. Acta Neurol Scand 87: 43-46.
10. Poser CM et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231.
11. Kurtzke JF. (1955) A new scale for evaluating disability in multiple sclerosis. Neurology 5: 580-583.
12. Kurtzke JF. (1961) On the evaluation of disability in multiple sclerosis. Neurology 11: 686-694.
13. Kurtzke JF. (1965) Further notes on disability evaluations in multiple sclerosis with scale modifications. Neurology 15: 654-661.
14. Kurtzke JF. (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33: 1444-1452.
15. International Federation of Multiple Sclerosis Societies. (1984) Symposium on a minimal record of disability in multiple sclerosis. Acta Neurol Scand (Suppl 101).
16. Hauser SL et al. (1983) Intensive immunosuppression in progressive multiple sclerosis: a randomized, three arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med 308: 173-180.
17. Sipe JC et al, (1988) A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 34: 1368-1372.
18. Willoughby EW, Paty DW. (1988) Scales for rating impairment in multiple sclerosis: a critique. Neurology 38: 1793-1798.
19. Amato MP et al. (1988) Interrater reliability in assessing functional systems and disability on the Kurtzke scale in multiple sclerosis. Arch Neurol 45: 746-748.
20. Noseworthy JH et al. (1990) Canadian Cooperative MS Study Group. Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. Neurology 40: 971-975.
21. Francis DA, Bain P, Swan AV, Hughes RAC. (1991) An assessment of disability scales used in multiple sclerosis. Arch Neurol 48: 299-301.
22. Goodkin DE et al. (1992) Inter- and intrarater variability for grades 1.0-3.5 of the Kurtzke expanded disability status scale (EDSS). Neurology 42: 859-863.
23. Noseworthy JH. (1996) Clinical scoring methods for multiple sclerosis. Ann Neurol 39: 285-294.
24. Sharrack B, Hughes AC. (1996) Clinical scales for multiple sclerosis. J Neurol Sci 135: 1-9.
25. Rudick R et al. (1996) Clinical outcomes assessment in multiple sclerosis. Ann Neurol 40: 469-479.
26. Waubant EL, Goodkin DE. (1996) Assessing efficacy in clinical trials of treatments for multiple sclerosis: issues and controversy. CNS Drugs 6: 462-473.
27. Weinshenker BG et al. (1989) The natural history of multiple sclerosis: a geographically based study: I. clinical course and disability. Brain 112: 133-146.
28. Cohen RA, Kessler HR, Fischer M. (1993) The expanded disability status scale (EDSS) as a predictor of impairments of functional activities of daily living in multiple sclerosis. J Neurol Sci 115: 132-135.
29. Rodriguez M et al. (1994) Impairment, disability, and handicap in multiple sclerosis: a population based study in Olmsted County, Minnesota. Neurology 44: 28-33.
30. Midgard R, Riise T, Nyland H. (1996) Impairment, disability, and handicap in multiple sclerosis: a cross-sectional study in an incident cohort in More and Romsdal County, Norway. J Neurol 243: 337-344.
31. Lublin FD, Reingold SC. (1996) Defining the clinical course of multiple sclerosis. Neurology 46: 907-911.
32. The IFNB Study Group. (1993) Interferon beta-1b is effective in remitting/relapsing multiple sclerosis: I. clinical results of a multicenter randomized, placebocontrolled trial. Neurology 43: 655-661.
33. The UBC MS/MRI Study Group and the IFNB Study Group. (1993) Interferon beta-1b is effective in remitting/ relapsing multiple sclerosis: II. MRI analysis results of a multicenter randomized, placebo-controlled trial. Neurology 43: 662-667.
34. The IFNB Study Group and the UBC MS/MRI Study Group. (1995) Interferon beta-1b in the treatment of multiple sclerosis: final results of the randomized controlled trial. Neurology 45: 1277-1285.
35. Jacobs LD et al. (1996) Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol 39: 285-294.
36. Johnson KP et al. (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 45: 1268-1276.